
Legend Biotech (LEGN) Stock Forecast & Price Target
Legend Biotech (LEGN) Analyst Ratings
Bulls say
Legend Biotech is supported by Carvykti’s durable, best-in-class clinical profile, including 60.5-month median PFS and 69.2% five-year OS, which reinforces its advantage in multiple myeloma and strengthens adoption in 2L/3L and potentially earlier lines. Commercially, the franchise is still growing despite competitive pressure, with management noting 50% of patients now treated in 2L/3L, 80% of patients not BCMA-exposed, and continued expectations for double-digit growth as US and ex-US expansion broaden the opportunity. Financially, 3Q26 revenue of $360M, gross margin in the high 50s, and $853M in cash with cash flow positivity point to improving profitability, lower funding risk, and room for margin expansion.
Bears say
Legend Biotech is highly dependent on Carvykti, so any stumble in CARTITUDE-5/6, slower 2-3L adoption, or manufacturing bottlenecks could materially weaken revenue growth and delay profitability. The company’s 3Q26 US sales were flat QoQ, while management implied 4Q26 revenue of about $722M versus consensus near $740M, signaling only modest sequential improvement and raising concern that the market may be near a growth plateau. With roughly half of 4L+ US revenue still exposed to anito-cel competition starting 1Q27 and broader risks from safety, reimbursement, and regulatory hurdles, its concentrated and high-risk profile supports a negative outlook.
This aggregate rating is based on analysts' research of Legend Biotech and is not a guaranteed prediction by Public.com or investment advice.
Legend Biotech (LEGN) Analyst Forecast & Price Prediction
Start investing in Legend Biotech (LEGN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Legend Biotech (LEGN) Forecast
Legend Biotech (LEGN) Analyst Forecast & Price Prediction
Start investing in Legend Biotech (LEGN)
Order type
Buy in
Order amount
Est. shares
0 shares